v3.26.1
Asset Acquisition - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended
May 18, 2026
Jun. 12, 2025
May 31, 2026
Jun. 30, 2026
Dec. 31, 2025
Business Combination [Line Items]          
Common stock, shares issued (in shares)       1,017,063 278,627
Private Placement          
Business Combination [Line Items]          
Common stock, shares issued (in shares)   33,360      
Aggregate gross proceeds of private placement   $ 11,500      
Series C Preferred Stock          
Business Combination [Line Items]          
Exercise of Warrants     $ 11,000    
Orphai Therapeutics [Member]          
Business Combination [Line Items]          
No of common stock issued 162,971        
Common stock, shares issued (in shares) 1,308,804        
Exercise of Warrants $ 72,000        
Number of common shares issuable upon conversion of preferred stock 7,498,447        
Financing Warrants to purchase stock 3,749,231        
Warrants to purchase common stock (in USD per share) $ 19.17     $ 19.17  
Acquisition costs $ 2,100        
Fair value of total consideration transferred 56,864        
Orphai Therapeutics [Member] | Private Placement          
Business Combination [Line Items]          
Aggregate gross proceeds of private placement 187,000        
Upfront proceeds 115,000        
Exercise of Warrants $ 72,000        
Orphai Therapeutics [Member] | Orphai Warrants          
Business Combination [Line Items]          
Financing Warrants to purchase stock 570,169        
Orphai Therapeutics [Member] | Series C Preferred Stock          
Business Combination [Line Items]          
No of common stock issued 67,101.235        
Convertible preferred stock, shares issued upon conversion       570,169  
Stock issued during period shares acquisitions 144,200.633        
Shares issued, price per share $ 797.5        
Financing Warrants to purchase stock 72,100.322        
Warrants to purchase common stock (in USD per share) $ 996.9     $ 996.9  
Orphai Therapeutics [Member] | Series C Preferred Stock | Orphai Warrants          
Business Combination [Line Items]          
Financing Warrants to purchase stock 10,964.505        
Orphai Therapeutics [Member] | Common Stock [Member]          
Business Combination [Line Items]          
No of common stock issued 162,971        
Convertible preferred stock, shares issued upon conversion 52        
Orphai Therapeutics [Member] | Common Stock [Member] | Series C Preferred Stock          
Business Combination [Line Items]          
Convertible preferred stock, shares issued upon conversion 52